Trial Profile

A clinical study of XRx-026 for the treatment of individuals who have gout and are intolerant to allopurinol

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Sep 2025 According to a XORTX Therapeutics media release, Dr. Allen Davidoff will discuss the company's clinical development programs, including the late-stage XRx-026 (XORLO) trial for allopurinol-intolerant gout, during an investor webinar and Q&A scheduled for September 10, 2025.
03 Sep 2025 According to a XORTX Therapeutics media release, company anticipates submission of the IND in the second half of 2025. The submission of the IND follows the Type B meeting that was held in April 2025 with the U.S. Food and Drug Administration.
30 Apr 2025 According to a XORTX Therapeutics media release, company announced that the gout NDA may be filed in the H1 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com